Thrombosis modulates arterial drug distribution for drug-eluting stents

Circulation

Volumn 111, Issue 13, 2005, Pages 1619-1626

  Hwang, Chao Wei ^a,b,c   Levin, Andrew D ^a   Jonas, Michael ^a,b   Li, Pamela H ^a   Edelman, Blazer R ^a,b  

^a HARVARD MIT DIVISION OF HEALTH SCIENCES AND TECHNOLOGY   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

Drugs; Restenosis; Stents; Thrombosis; Thrombus

Indexed keywords

FIBRIN; PACLITAXEL;

ARTICLE; BLOOD CLOT; BLOOD COMPONENT; CELL FRACTIONATION; CONTROLLED STUDY; DRUG DIFFUSION; DRUG DISTRIBUTION; DRUG ELUTING STENT; DRUG RETENTION; ERYTHROCYTE; LINEAR SYSTEM; NONHUMAN; PREDICTION; PRIORITY JOURNAL; REGULATORY MECHANISM; THROMBOCYTE ADHESION; THROMBOSIS; VALIDATION PROCESS;

ANIMALS; ARTERIES; BLOOD COAGULATION; COMPUTER SIMULATION; DIFFUSION; HUMANS; MALE; PACLITAXEL; PHARMACOKINETICS; RATS; RATS, SPRAGUE-DAWLEY; STENTS; THROMBOSIS; TISSUE DISTRIBUTION;

EID: 17144368424     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000160363.30639.37     Document Type: Article

References (24)

1. Holmes DR Jr, Leon MB, Moses JW, Popma JJ, Cutlip D, Fitzgerald PJ, Brown C, Fischell T, Wong SC, Midei M, Snead D, Kuntz RE. Analysis of 1-year clinical outcomes in the SIRIUS trial: a randomized trial of a sirolimus-eluting stent versus a standard stent in patients at high risk for coronary restenosis. Circulation. 2004;109:634-640.
2. Sheiban I, Moretti C, Oliaro E, Catuzzo B, Destefanis P, Carrieri L, Sciuto F, Grosso Marra W, Omede PL, Gagnor A, Truffa A, Trevi GP. Evolving standard in the treatment of coronary artery disease: drug-eluting stents. Minerva Cardioangiol. 2003;51:485-492.
3. Stone GW, Ellis SG, Cox DA, Hermiller J, O'Shaughnessy C, Mann JT, Turco M, Caputo R, Bergin P, Greenberg J, Popma JJ, Russell ME. One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting TAXUS stent; the TAXUS-IV trial. Circulation. 2004;109:1942-1947.
4. Edelman ER, Lovich M. Drug delivery models transported to a new level. Nat Biotechnol. 1998;16:136-137.
5. Lovich MA, Edelman ER. Tissue concentration of heparin, not administered dose, correlates with the biological response of injured arteries in vivo. Proc Natl Acad Sci U S A. 1999;96:11111-11116.
6. Hwang CW, Edelman ER. Arterial ultrastructure influences transport of locally delivered drugs. Circ Res. 2002;90:826-832.
7. Hwang CW, Wu D, Edelman ER. Physiological transport forces govern drug distribution for stent-based delivery. Circulation. 2001;104:600-605.
8. Sakharov DV, Kalachev LV, Rijken DC. Numerical simulation of local pharmacokinetics of a drug after intravascular delivery with an eluting stent. J Drug Target. 2002;10:507-513.
9. Stone GW, Cox DA, Babb J, Nukta D, Bilodeau L, Cannon L, Stuckey TD, Hermiller J, Cohen EA, Low R, Bailey SR, Lansky AJ, Kuntz RE. Prospective, randomized evaluation of thrombectomy prior to percutaneous intervention in diseased saphenous vein grafts and thrombus-containing coronary arteries. J Am Coll Cardiol. 2003;42:2007-2013.
10. Kereiaks DJ, Choo JK, Young JJ. Thrombosis and drug-eluting stents: a critical appraisal. Rev Cardiovasc Med. 2004;5:9-15.
11. Schwartz RS. Pathophysiology of restenosis: interaction of thrombosis, hyperplasia, and/or remodeling. Am J Cardiol. 1998;81:14E-17E.
12. Edelman ER, Rogers C. Pathobiologic responses to stenting. Am J Cardiol. 1998;81:4E-6E.
13. Jeremias A, Sylvia B, Bridges J, Kirtane AJ, Bigelow B, Pinto DS, Ho KK, Cohen DJ, Garcia LA, Cutlip DE, Carrozza JP Jr. Stent thrombosis after successful sirolimus-eluting stent implantation. Circulation. 2004;109:1930-1932.
14. Grube E, Gerckens U, Muller R, Bullesfeld L. Drug eluting stents: initial experiences. Z Kardiol. 2002;91(suppl 3):44-48.
15. Welt FG, Edelman ER, Vukmirovic N, Rogers C. Stent release of a rapamycin analogue: tissue pharmacokinetics of rapid versus delayed release. J Am Coll Cardiol. 2003;41:74A.
16. Blinc A, Francis CW. Transport processes in fibrinolysis and fibrinolytic therapy. Thromb Haemost. 1996;76:481-491.
17. Creel CJ, Lovich MA, Edelman ER. Arterial Paclitaxel distribution and deposition. Circ Res. 2000;86:879-884.
18. Penn MS, Rangaswamy S, Saidel GM, Chisolm GM. Macromolecular transport in the arterial intima: comparison of chronic and acute injuries. Am J Physiol. 1997;272:H1560-H1570.
19. Lovich MA, Creel CJ, Hong K, Hwang CW, Edelman ER. Carrier proteins determine local pharmacokinetics and arterial distribution of paclitaxel. J Pharm Sci. 2001;90:1324-1335.
20. Levin AD, Vukmirovic N, Hwang CW, Edelman ER. Specific binding to intracellular proteins determines arterial transport properties for rapamycin and paclitaxel. Proc Natl Acad Sci U S A. 2004;101:9463-9467.
21. Manfredi JJ, Parness J, Horwitz SB. Taxol binds to cellular microtubules. J Cell Biol. 1982;94:688-696.
22. Lansky AJ, Costa RA, Mintz GS, Tsuchiya Y, Midei M, Cox DA, O'Shaughnessy C, Applegate RA, Cannon LA, Mooney M, Farah A, Tannenbaum MA, Yakubov S, Kereiakes DJ, Wong SC, Kaplan B, Cristea E, Stone GW, Leon MB, Knopf WD, O'Neill WW. Non-polymer-based paclitaxel-coated coronary stents for the treatment of patients with de novo coronary lesions: angiographic follow-up of the DELIVER clinical trial. Circulation. 2004;109:1948-1954.
23. Diamond SL. Engineering design of optimal strategies for blood clot dissolution. Annu Rev Biomed Eng. 1999;1:427-462.
24. Zidansek A, Blinc A. The influence of transport parameters and enzyme kinetics of the fibrinolytic system on thrombolysis: mathematical modelling of two idealised cases. Thromb Haemost. 1991;65:553-559.